Publication date: Jun 30, 2025
Biomarkers based on host response signatures are currently under development for the critically ill. We applied a 29-mRNA classifier for the diagnosis and prognosis of suspected acute infection and sepsis (TriVerity, Inflammatix Inc. ) in patients hospitalized with COVID-19. We applied three scores from locked classifiers (IMX-BVN-4 and IMX-SEV-4) from the 29-mRNA TriVerity blood test in participants of the SAVE-MORE randomized clinical trial (ClinicalTrials. gov NCT04680949) at baseline and days 4 and 7 of treatment, to classify bacterial infection, viral infection and decompensation. Participants were adults hospitalized with confirmed COVID-19 pneumonia and plasma soluble urokinase plasminogen activator receptor (suPAR) levels of ≥ 6 ng/ml, randomized to placebo or anakinra treatment. A total of 471 patients were studied. At baseline nearly 90% had a Very Low or Low IMX-BVN-4 Bacterial Score and Moderate, High or Very High IMX-BVN-4 Viral Score. Anakinra treatment had an effect on the expression of genes indicating IMX-SEV-4 High or Very High scores after a 7 day treatment compared to baseline (12. 9% of anakinra-treated patients continued being classified as high severity vs 20. 4% of placebo-treated patients, p 0. 046). The classifiers were well tested in COVID-19 pneumonia and may become a useful tool for hospitalized patients.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | host |
| disease | MESH | bacterial infection |
| disease | MESH | viral infection |
| disease | MESH | disease progression |
| disease | MESH | COVID-19 |
| disease | MESH | pneumonia |
| disease | MESH | critically ill |
| disease | IDO | acute infection |
| disease | MESH | sepsis |
| disease | IDO | blood |
| drug | DRUGBANK | Anakinra |
| disease | MESH | Secondary infection |